Purchase of MVE Fusion Self-Sustaining Cryogenic Freezers

项目摘要 该请求的目标是安装两台创新的Chart MVE Fusion 1500自维持低温冷冻机 通过创建一个共享的新低温冷冻农场， 研究所的低温储存能力新的cryofezer农场将支持35个活跃的研究实验室和核心 设施以及具有知识产权价值的研究样品的储存。由于额外的冷冻机不能 由于空间限制和翻新，无法尝试扩大现有的农场设施， 现有农场的足迹，建立一个新的冷冻农场是至关重要的Wistar研究人员扩大他们的 目前的使用，以支持92 NIH资助的项目，并追求研究和发现的新方向。两 尖端的、独立的、自我维持的低温冷冻机将能够创建一个新的、增加的低温冷冻机农场 在研究所的塔楼地下室（B 02室）内，不需要管道提供外源性 更换液氮。值得注意的是，Chart MVE Fusion自维持冰柜采用创新的Qdrive 低温冷却技术仅在50升液氮上运行，并且在初始液体冷却后仅在电力上运行。 氮气填充，因此不需要额外更换液氮。Chart MVE Fusion 1500低温 Freezer是世界上第一个使用专利Qdrive Cryo-cooler技术的冷冻机， 重复使用现有供应的液氮以保持冷冻机温度。相比之下，传统的气相 低温冷冻机需要80升液氮用于初始填充，然后是随后的日常填充， 用于因使用和蒸发而导致的液氮损失。所要求的MVE Fusion 1500冷冻机将解决 同时满足两项科学需求：（a）扩大低温储存能力，增加72个储存空间 机架，以跟上研究所的增长步伐，以及（B）在新的地点建立冷冻装置，而无需 随着研究所向自我维持的绿色技术过渡，提供持续的液氮供应。我们 我将通过实施一个具体目标来满足这些需求，即安装两台Chart MVE Fusion 1500， 在Wistar研究所建立一个共享的卫星低温冷冻农场。全新MVE Fusion 冷冻机将由Wistar的运营部管理，并由副总裁Luis Montaner博士监督。 科学运营总裁和共享资源副主任，代表教师在 威斯塔研究所。Wistar研究所是美国历史最悠久的独立生物医学研究所， 充满活力和高度合作的教师谁执行癌症生物学，免疫学， 和疫苗。该研究所在单克隆抗体治疗和癌症方面拥有悠久的研究成功历史 生物（Stelara®）和疫苗（RotaTeq©），包括第二种进入临床的COVID-19疫苗 在美国进行测试。

Project Summary The goal of this request is to install two innovative Chart MVE Fusion 1500 self-sustaining Cryogenic freezers for -150oC to -190oC temperature long-term storage by creating a shared new cryofreezer farm which will expand the Institute’s cryostorage capabilities. The new cryofeezer farm will support 35 active research labs and core facilities as well as storage of research samples with intellectual property value. As additional freezers cannot be added to the current farm facility due to space constrains and renovations cannot be attempted to expand the footprint of the existing farm, creation of a new cryofreezer farm is critical for Wistar researchers to expand their current usage to support 92 NIH-funded projects and pursue new directions of research and discovery. Two cutting-edge, stand-alone, self-sustaining cryofreezers will enable creation of a new, added cryofreezer farm within the tower basement of the Institute (room B02) and without a need for pipelines providing exogenous replacement of liquid nitrogen. Notably, Chart MVE Fusion self-sustaining freezers utilize innovative Qdrive cryocooling technology to operate on only 50 liters of liquid nitrogen and run solely on electricity after initial liquid nitrogen fill, thus not requiring added replacement of liquid nitrogen. The Chart MVE Fusion 1500 cryogenic Freezer is the world’s first cryofreezer to use patented Qdrive Cryo-cooler technology to remove heat from and reuse existing supplied liquid nitrogen to maintain freezer temperature. By contrast, traditional vapor phase cryofreezers require 80 liters of liquid nitrogen for initial fill and then subsequent daily routine filling to compensate for liquid nitrogen loss due to usage and evaporation. The requested MVE Fusion 1500 cryofreezers will address two scientific needs at the same time: (a) the expansion of cryostorage capabilities with 72 additional storage racks to keep pace with Institute growth, and (b) establish cyofreezer units in a new location without the need to provide constant liquid nitrogen supply as the Institute transitions towards self-sustaining green technology. We will address these needs by implementing a specific aim to install two Chart MVE Fusion 1500 self-sustaining cryofreezers and create a shared satellite cryofreezer farm at The Wistar Institute. The new MVE Fusion cryofreezers will be managed by Wistar’s Department of Operations and overseen by Dr. Luis Montaner, Vice President of Scientific Operations and Associate Director for Shared Resources, on behalf of the faculty at the Wistar Institute. The Wistar Institute is the nation’s oldest independent biomedical research institute, with an energized and highly collaborative faculty who perform cutting-edge research on cancer biology, immunology and vaccines. The Institute boasts a long history of research success in monoclonal antibody therapy and cancer biology (Stelara®) and vaccines (RotaTeq©), including the second COVID-19 vaccine to move into clinical testing in the United States.